EMA Authorised: Daptomycin Hospira (daptomycin) — Pfizer Europe MA EEIG

View source ↗

Summary

The EMA authorised Daptomycin Hospira (daptomycin) for marketing in the EU for soft tissue infections and bacterial skin infections, with decision date 19 Janua…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bacterial Skin Infection
• Soft Tissue Infection

Drugs mentioned

• Daptomycin Hospira (daptomycin)

Snippet

Status: Authorised. Therapeutic area: Soft Tissue Infections;Skin Diseases, Bacterial. MAH: Pfizer Europe MA EEIG. Decision date: 19/01/2026